Neovascular age-related macular degeneration

Ophthalmologica

Volumn 227, Issue SUPPL. 1, 2012, Pages 11-20

  Veritti, Daniele ^a   Sarao, Valentina ^a   Lanzetta, Paolo ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Aflibercept; Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Pegaptanib; Ranibizumab

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; EYLEA; MP 0112; PARVOVIRUS VECTOR; PEGAPTANIB; RANIBIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VEGF TRAP EYE;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLEEDING; DEATH; DRUG EFFICACY; DRUG INFORMATION; DRUG RESEARCH; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERTENSION; NONHUMAN; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; STROKE; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; HUMANS; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84860186303     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000337154     Document Type: Article

References (30)

1. Klein R, Peto T, Bird A, Vannewkirk MR: The epidemiology of age related macular degeneration. Am J Ophthalmol 2004; 137: 486-495. (Pubitemid 38328641)
2. Zarbin MA: Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122: 598-614.
3. Grisanti S, Tatar O: The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 2008; 27: 372-390.
4. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf JL, Gill SC, Bendele RA: Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 2000; 17: 1503-1510. (Pubitemid 32217559)
5. Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D: Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008; 92: 1606-1611.
6. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-2182. (Pubitemid 350181137)
7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
8. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
9. Drugs.com - 12-month results from DENALI study evaluating verteporfin PDT (Visudyne) combination therapy. www.drugs.com/clinical-trials/12-month-results- denali-study-evaluating-verteporfin-pdt-visudyne-combination-therapy-9634.html (accessed Jan 2012).
10. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A, EXCITE Study Group: Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118: 831-839.
11. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
12. Heier JS: VEGF Trap-Eye for AMD: VIEW 1/ VIEW 2 Studies. Retina Subspecialty Day. Orlando, American Academy of Ophthalmology Annual Meeting, 2011.
13. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239-248.
14. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58.
15. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, SUSTAIN Study Group: Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118: 663-671.
16. Dixon JA, Oliver SC, Olson JL, Mandava N: VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2009; 18: 1573-1580.
17. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U, Tübingen Bevacizumab Study Group: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823. (Pubitemid 351261238)
18. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-1047. (Pubitemid 40797459)
19. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-859. (Pubitemid 46635858)
20. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850. (Pubitemid 32119100)
21. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T: Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010; 94: 1215-1218.
22. Curtis LH, Hammill BG, Schulman KA, Cousins SW: Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128: 1273-1279.
23. Carneiro AM, Barthelmes D, Falcão MS, Mendonça LS, Fonseca SL, Gonçalves RM, Faria-Correia F, Falcão-Reis FM: Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 2011; 225: 211-221.
24. Gower EW, Cassard S, Chu L, Varma R, Klein R: Adverse event rates following intravitreal injection of Avastin or Lucentis for treating age-related macular degeneration (abstract 6644). Fort Lauderdale, ARVO Meeting, 2011.
25. Lai TY, Everest Study Group: Verteporfin PDT and ranibizumab combination therapy for symptomatic macular polypoidal choroidal vasculopathy (PCV): EVEREST results (abstract 2228/A327). Fort Lauderdale, ARVO Meeting, 2010.
26. Gutfleisch M, Heimes B, Schumacher M, Dietzel M, Lommatzsch A, Bird A, Pauleikhoff D: Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD. Eye 2011; 25: 1181-1186.
27. Hemeida TS, Keane PA, Dustin L, Sadda SR, Fawzi AA: Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. Br J Ophthalmol 2010; 94: 701-705.
28. Drugs.com - QLT announces 12-month results from Novartis-sponsored MONT BLANC study evaluating standard-fluence Visudyne combination therapy. www.drugs.com/clinical-trials/qlt-announces-12-month-results-novartis-sponsored- montblanc-study-evaluat ing-standard-fluence-7584.html (accessed Jan 2012)
29. Tao Y, Jonas JB: Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration. J Ocul Pharmacol Ther 2010; 26: 207-212.
30. Augustin AJ, Puls S, Offermann I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-140.